CERTIFICATION OF FACSIMILE TRANSMISSION								
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.								
	Type or print name of person signing certification							
	, , , , , , , , , , , , , , , , , , ,							
	Signature	Date						

PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. : US 7,282,595

Issued: : October 16, 2007

First Applicant : MADER, Mary Margaret

Serial No. : 10/535,002

Application Date : November 13, 2003

US Nat'l Entry Date : May 12, 2005

(if applicable):

Entitled : ANTITUMOR BENZOYLSULFONAMIDES

Docket No. : X-16114

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. 1.322

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The patentee of the above-identified patent respectfully requests that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. Attached is a copy of Form PTO 1050 on which the errors are specified.

Respectfully submitted,

/Tina M. Tucker/ Tina M. Tucker Attorney for Applicants Registration No. 47,145 Phone: 317-277-3537

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
June 25, 2010

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page <u>1</u> of <u>1</u>

PATENT NO. : US 7,282,595

APPLICATION NO. 10/535,002

ISSUE DATE : October 16, 2007

INVENTOR(S) : MADER Mary Margaret, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The priority date (November 22, 2002) was not printed on the front page of the above-referenced patent although the record reflects that the priority was reported to the USPTO. For your convenience, we have attached a copy of the Transmittal Letter (dated May 12, 2005) to this Certificate.

MAILING ADDRESS OF SENDER (Please do not use customer number below): Eli Lilly and Company

P. O. Box 6288

Indianapolis, IN 46206-6288

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): Mary Margaret MADER, Luisa MARTIN, and Michael Enrico RICHETT

International Application No.: PCT/US2003/035041

Filed: 13 November 2003 (13.11.2003)

Invention: ANTITUMOR BENZOYLSULFONAMIDES

Lilly Reference: X16114

Earliest Priority Date: 22 November 2002 (22.11.2002)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for P

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

ZUBPBOETELEA

Sir/Madam:

"Express Mail" mailing label number: <u>EV 393130848 US</u>

Date of Deposit: <u>I 2 M M 2005</u>

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Synature of person mailing paper or fee)

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)				ATTORNEY'S DOCKET NUMBER						
				X16114 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)						
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)				One has enoughous too far anomal see 25 Circle (23)						
CONCERNING A FILING UNDER 35 U.S.C. 371										
	RNATIONAL APPLICATION NO. PCT/US2003/035041	INTERNATIONAL FILING	;	PRIORITY DATE CLAIMED						
	FC1/032003/033041	13 November 2003		22 November 2002 (22.11.2002)						
		(13.11.2003)		(
TITLE	OF INVENTION: ANTITUMOR E	BENZOYLSULFONAMIDI	ES							
				IN, and Michael Enrico RICHETT						
Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:										
1. X	X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3.	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay									
	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).									
4. X	• •	diminary Examination was made	by th	e 19th month from the earliest claimed						
. [priority date.	0) 2 20 8 70 0 0 0 0 0 0 1 (20)								
5. X	A copy of the International Application		.							
		ired only if not transmitted by the	e inie	rnational Bureau).						
	b. has been transmitted by the I									
, \Box	c. X is not required, as the applica			,						
6.	A translation of the International Appli									
7. X	Amendments to the claims of the Intere	- '								
		nired only if not transmitted by t	he Int	ernational Bureau).						
	b. have been transmitted by the									
	[r, the time limit for making such	amen	dments has NOT expired.						
<u>"</u> П	d. X have not been made and will			CL 2011-3/03						
8.	A translation of the amendments to the		0.5.	C. 5/1(0)(3)3.						
9. X 10. X	An oath or declaration of the inventor(s) A declaration of the inventors 35 U.S.C		ו יויינט	P X2						
11. X				eg any annexes, and, if not in English, an						
لــا										
,	English language translation of the annual to 18. below concern document(s) o		C18 39	5 (33 U.S.C. 371(6)(3)).						
12. X	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.								
13. <u>X</u>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
14.	Assignment has been recorded at reel, frame									
15.	A FIRST preliminary amendment.	A FIRST preliminary amendment.								
16.	A SECOND or SUBSEQUENT prelin	A SECOND or SUBSEQUENT preliminary amendment.								
17.	A Sequence Listing, 1.821 Statement,	***************************************								
18. X	A power of attorney with attachments.									
10. X	Other items or information:	and the second s								
	Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US2003/035041, filed 13 November 2003, which, claims the benefit, under 35 USC 119(e), of US provisional application 60/428,891, filed 22 November 2002."									
[PAGE 1 OF 2]										

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.	X16114						
19. X The following	ng fees are submitted			CALCULATIONS	PTO USE ONLY			
Basic National S	~			***************************************				
National Stage S	earch Fee =							
	ixamination Fee = ATIONAL STAGE I							
Application Len	gth Fee							
Total Length (excluding sequen	ce listings)							
27 - 100) = 0 excess pages (b)						
No extra charge fo thereof).	r first 100 pages. Must	**************************************						
				01.000.00				
		PPROPRIATE AMO		\$1,000.00				
from the earliest claim		h or declaration later than. "FR 1 492(e))	ou montas	\$				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		L			
Total claims	5-20≈		X \$50.00					
Independent claims	3-3=	*	X \$200.00	\$				
MULTIPLE DEPEND	ENT CLAIM(S) (if	applicable)	+ \$360.00	\$				
	TOTA	L OF ABOVE CAL	CULATIONS =	\$ 0.00				
Reduction by 1/2 for fi Statement must also be		if applicable. Verified Sm 1.9, 1.27, 1.28).	all Entity	\$				
			SUBTOTAL =	\$1,000.00				
Processing fee of \$130 from the earliest claim		glish translation later than FR 1.492(f)).	30 months	\$				
A. V.			IONAL FEE =	\$1,000.00				
Fee for recording the e		37 CFR 1.21(h)). The ass		\$				
accompanies by an app	proprime vorus sinoi		10.00 per property	•				
		\$1,000.00						
				Amount to be refunded	\$			
				charged	\$			
b. X Please charg								
copy of this sheet is enclosed. c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any								
overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO:								
ELILILLY AND COM	PANY	ģģģāns (rāss) deno grass rask:	2 KIN 3892					
PATENT DIVISION P.O. BOX 6288								
INDIANAPOLIS, INDIA			128 ME					
***************************************	2005	2588	•					
Date 47,145 (317) 277-3537				PATENT TRADEMAR	ek office			
REGISTRATION NUME	BER	TELEPHONE NUMBER						